Trial Profile
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2015
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis virus infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 28 May 2015 New trial record